Human Reproduction, Vol. 10, No. 10, pp. 2534-2540, 1995
© 1995 European Society of Human Reproduction and Embryology
research-article |
A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization
1Section Reproductive Medicine and 2Biometrics, Medical Research and Development Unit NV Organon, PO Box 20, 5340 BH Oss, The Netherlands
Correspondence: *To whom correspondence should be addressed
Urinary follicle stimulating hormone (FSH) is being used for the treatment of human infertility. Recently, FSH manufactured by means of recombinant DNA technology with a much higher purity (>99%) has become available. A prospective, randomized, assessor-blind, multicentre (n = 18) study was conducted in infertile women undergoing in-vitro fertilization comparing recombinant FSH (Org 32489, Puregon®) and urinary FSH (Metrodin®). Eligible subjects were randomized (recombinant versus urinary FSH = 3:2) and pretreated with buserelin for pituitary suppression. FSH was given until three or more follicles with a diameter of at least 17 mm were seen. After oocyte retrieval, fertilization routines were applied according to local procedures. No more than three embryos were replaced. In all, 585 subjects received recombinant FSH and 396 urinary FSH. Significantly more oocytes were retrieved after recombinant FSH treatment (mean adjusted for centre 10.84 versus 8.95, P < 0.0001). Ongoing pregnancy rates per attempt and transfer in the recombinant FSH group were 22.17 and 25.97% respectively, and in the urinary FSH group, 18.22 and 22.02% respectively (not significant). Ongoing pregnancy rates including pregnancies resulting from frozen-thawed embryo cycles were 25.7% for recombinant and 20.4% for urinary FSH (P = 0.05). Compared to urinary FSH, the total dose of FSH was significantly lower with recombinant FSH (2138 versus 2385 IU, P < 0.0001) in a significantly shorter treatment period (10.7 versus 11.3 days, P < 0.0001). No clinically relevant differences between recombinant and urinary FSH were seen with respect to safety variables. It is concluded that recombinant FSH (Puregon) is more effective than urinary FSH in inducing multifollicular development and achieving an ongoing pregnancy.
Key words: IVF/ovarian stimulation/Puregon/recombinant FSH
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Demirol and T. Gurgan Comparison of different gonadotrophin preparations in intrauterine insemination cycles for the treatment of unexplained infertility: a prospective, randomized study Hum. Reprod., January 1, 2007; 22(1): 97 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Arce, A. Nyboe Andersen, and J. Collins Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review Hum. Reprod., July 1, 2005; 20(7): 1757 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lunenfeld Historical perspectives in gonadotrophin therapy Hum. Reprod. Update, November 1, 2004; 10(6): 453 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Huang, K.-C. Lan, F.-T. Kung, M.-Y. Tsai, C.-Y. Chang, H.-W. Huang, Y.-C. Lin, and S.-Y. Chang Human cumulus-free oocyte maturational profile and in vitro developmental potential after stimulation with recombinant versus urinary FSH Hum. Reprod., February 1, 2004; 19(2): 306 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Al-Inany, M. Aboulghar, R. Mansour, and G. Serour Meta-analysis of recombinant versus urinary-derived FSH: an update Hum. Reprod., February 1, 2003; 18(2): 305 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.E.F. Zwart-van Rijkom, F.J. Broekmans, and H.G.M. Leufkens From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study Hum. Reprod., April 1, 2002; 17(4): 857 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Harlin, A. Aanesen, G. Csemiczky, H. Wramsby, and G. Fried Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation Hum. Reprod., February 1, 2002; 17(2): 304 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sykes, H. J. Out, S. J. Palmer, and J. v. Loon The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Hum. Reprod., December 1, 2001; 16(12): 2557 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Daya, W. Ledger, J.P. Auray, G. Duru, K. Silverberg, M. Wikland, R. Bouzayen, C.M. Howles, and A. Beresniak Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK Hum. Reprod., December 1, 2001; 16(12): 2563 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, I. David, R. Ron-El, S. Friedler, E. Shalev, J. Geslevich, J. Dor, A. Shulman, Z. Ben-Rafael, B. Fisch, et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles Hum. Reprod., June 1, 2001; 16(6): 1104 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Y. Ng, E. Y. L. Lau, W. S. B. Yeung, and P. C. Ho HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial Hum. Reprod., February 1, 2001; 16(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Filicori, G. E. Cognigni, S. Taraborrelli, D. Spettoli, W. Ciampaglia, C. Tabarelli de Fatis, P. Pocognoli, B. Cantelli, and S. Boschi Luteinzing Hormone Activity in Menotropins Optimizes Folliculogenesis and Treatment in Controlled Ovarian Stimulation J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 337 - 343. [Abstract] [Full Text]
|
|
|
|
|
|
G. Horsman, J.A. Talbot, J.D. McLoughlin, A. Lambert, and W.R. Robertson A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon Hum. Reprod., September 1, 2000; 15(9): 1898 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schats, P.D. Sutter, S. Bassil, J.A.M. Kremer, H. Tournaye, J. Donnez, and o. b. o. T. F. a. A. study group Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH Hum. Reprod., August 1, 2000; 15(8): 1691 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fleming, P. Rehka, N. Deshpande, M.E. Jamieson, R.W.S. Yates, and H. Lyall Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH Hum. Reprod., July 1, 2000; 15(7): 1440 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The European Orgalutran Study Group, G. Borm, and B. Mannaerts Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Hum. Reprod., July 1, 2000; 15(7): 1490 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Matorras, V. Recio, B. Corcostegui, and F.J. Rodriguez-Escudero Recombinant human FSH versus highly purified urinary FSH: a randomized study in intrauterine insemination with husbands' spermatozoa Hum. Reprod., June 1, 2000; 15(6): 1231 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lenton, A. Soltan, J. Hewitt, A. Thomson, W. Davies, N. Ashraf, V. Sharma, L. Jenner, W. Ledger, and E. McVeigh Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP) Hum. Reprod., May 1, 2000; 15(5): 1021 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Frydman, C.M. Howles, and F. Truong A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F(R)) with highly purified urinary FSH (Metrodin(R) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection Hum. Reprod., March 1, 2000; 15(3): 520 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, D. D.M. Braat, B. M.E. Lintsen, T. Gurgan, O. Bukulmez, O. Gokmen, G. Keles, P. Caballero, J. M. Gonzalez, F. Fabregues, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon(R)) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation Hum. Reprod., January 1, 2000; 15(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.M. Buckler, W.R. Robertson, A. Anderson, M. Vickers, and A. Lambert Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon) Hum. Reprod., December 1, 1999; 14(12): 2969 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tulppala, M. Aho, T. Tuuri, S. Vilska, T. Foudila, T. Hakala-Ala-Pietila, J. Moilanen, T. Butzow, S. Kaukoranta, V. Soderstrom-Anttila, et al. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study Hum. Reprod., November 1, 1999; 14(11): 2709 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H.M. Hoomans, A. N. Andersen, A. Loft, R. A. Leerentveld, A. A. van Kamp, and H. Zech A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon(R)) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP(R)) in a fixed-dose regimen in women undergoing ovarian stimulation Hum. Reprod., October 1, 1999; 14(10): 2442 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, H. J.T.C. Bennink, and W. N.G.M. de Laat What are the clinical benefits of recombinant gonadotrophins?: The development of recombinant FSH (Puregon(R)): a scientific business Hum. Reprod., September 1, 1999; 14(9): 2189 - 2190. [Full Text] [PDF]
|
|
|
|
|
|
S. Daya and J. Gunby Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction Hum. Reprod., September 1, 1999; 14(9): 2207 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kol, A. Lightman, T. Hillensjo, P. Devroey, B. Fauser, B. Tarlatzis, B. Mannaerts, and J. Itskovitz-Eldor High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze–thaw cycles Hum. Reprod., September 1, 1999; 14(9): 2242 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Voortman, J. van de Post, R. C. Schoemaker, and J. M.A. van Gerven Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe Hum. Reprod., July 1, 1999; 14(7): 1698 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I Meniru Is Puregon a `good' or `super' drug? Hum. Reprod., June 1, 1999; 14(6): 1409 - 1411. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Balen, C. J. Hayden, and A. J. Rutherford Clinical efficacy of recombinant gonadotrophins Hum. Reprod., June 1, 1999; 14(6): 1411 - 1417. [Full Text] [PDF]
|
|
|
|
|
|
C. Bergh Recombinant follicle stimulating hormone Hum. Reprod., June 1, 1999; 14(6): 1418 - 1420. [Full Text] [PDF]
|
|
|
|
|
|
F. Raga, F. Bonilla-Musoles, E.M. Casan, and F. Bonilla Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome Hum. Reprod., June 1, 1999; 14(6): 1431 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.G. Mantovani, A. Belisari, and T.D. Szucs Pharmaco-economic aspects of in-vitro fertilization in Italy Hum. Reprod., April 1, 1999; 14(4): 953 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, S. Lindenberg, A. L. Mikkelsen, T. Eldar-Geva, D. L. Healy, A. Leader, F. J. Rodriguez-Escudero, J. A. Garcia-Velasco, and A. Pellicer A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation Hum. Reprod., March 1, 1999; 14(3): 622 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Shoham, P. Devroey, H. Tournaye, A. Van Steirteghem, P. Hendrix, and H.J. Out Ovarian stimulation Hum. Reprod., March 1, 1999; 14(3): 864 - 865. [Full Text] [PDF]
|
|